



February 2022

Dear Optum360 2022 *Current Procedural Coding* Customer:

The American Medical Association (AMA) has issued the following updates. Additional information on these codes can be found at <https://www.ama-assn.org/practice-management/cpt>.

Included below are the changes that can be marked in your book. Our customer service team is available to answer any questions at 1.800.464.3649, option 1.

Thank you for your patience and support of our ongoing efforts to deliver high-quality products. We value you as an Optum360 customer.

Sincerely,

Optum360

www.optum360coding.com

The following codes are effective February 1, 2022, pending EUA/FDA approval:

New codes

- 0081A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
- 0082A second dose
- 91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

The following code is effective February 21, 2022:

New code

- 87913 Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)